Hensler Surgical Products to exhibit the Hensler Bone Press at NASS


Hensler Surgical Products has announced that its Hensler Bone Press will be launched at the North American Spine Society’s Annual Meeting (NASS), held in Dallas on Wednesday, October 24 through Saturday, October 27.

The inventor of the device, Sean Hensler, neurosurgical physicians assistant, will be present at Booth 2234 to display and demonstrate the device. The Hensler Bone Press collects bone after use of the high speed drill and separates autologous bone for immediate use in grafting procedures. Additionally, it acts as a sterile method to collect and contain tumours for pathology when combined with an ultrasonic device.

Hensler said: “I’m excited to showcase the Hensler Bone Press at the NASS Annual Meeting. Cost containment solutions for surgery have been a focus of mine, and I look forward to sharing how the HBP is a better option than the current and common processes, and on top of that, will be well-integrated into the surgery.”

A company press release states that the device has two primary applications:to collect and separate autologous bone without hindering the flow of the case, and when combined with an ultrasonic device, to offer a sterile method to collect tumours—doing away with the traditional use of the contaminated sock method.

For the collection of autologous bone, the bone press works in two capacities: through a suction port, it collects material from the surgical site. The full reservoir is then passed along to the scrub technician and the press head is pushed down, filtering out material, fluid and blood, thus harvesting viable bone to be used for grafting and fusion procedures as the case requires. The bone that is collected and compressed can be placed within inter-body grafts or lay-on grafting to reduce the need to rely on synthetic bone material and biologics.

The Hensler Bone Press is currently undergoing design controls and is expected to start trials and sales by November 2012. According to a company press release, more than 30 hospitals are expected to trial the device immediately. International sales are expected by February 2013.